Navigation Links
NeoStem Provides Updates, Reports Results for Third Quarter and Upcoming November Company Presentations
Date:11/11/2011

r 30, 2010, respectively. Please refer to our recently filed 10Q for a complete discussion about results of operations.

The Company invested $5.5 million in capital expenditures during the first nine months of 2011, primarily related to the construction of a new pharmaceutical manufacturing facility for its majority-owned subsidiary, Suzhou Erye Pharmaceutical Co., Ltd. ("Erye").

As of September 30, 2011, the Company had cash, cash equivalents and restricted cash of $18.1 million (note: $5 million of the $18 million is classified in Other Assets).

NeoStem believes that the opportunities that exist today in cell therapy are robust and growing within a persistently difficult financial environment, making this an opportunistic time to monetize the Company's 51% ownership of Erye and bolster its cell therapy business.  In June 2011, the Company engaged a financial advisor to lead the effort to pursue the possible divesture of the Company's interest in Erye.  Marketing efforts are underway and have generated interest from both financial and strategic buyers.

NeoStem continues to grow, devoting resources to its cell therapy business, including manufacturing, therapeutic development, and related activities.  On October 17, 2011 the company consummated the acquisition of Amorcyte, Inc., taking ownership of a strong patent portfolio covering the use of hematopoietic stem cells for treatment of cardiac ischemia.  Amorcyte's lead product candidate, AMR-001, is entering a Phase 2 study for the treatment of acute myocardial infarction. Amorcyte is currently recruiting trial sites in connection with the launch of this Phase 2 clinical trial, which is expected to begin patient enrollment by the end of the first quarter of 2012.

NeoStem continues to advance the development of Athelos Corporation's (a NeoStem company, partnered with Becton, Dickinson and Company) immunology platform. The Company's novel T-cell technology repr
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeoStem Announces Change in Presentation Time for JMP Securities Conference
2. NeoStem Announces Participation in Multiple September Conferences
3. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
4. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
5. NeoStem Announces Pricing of Public Offering for $16,500,000 in Gross Proceeds
6. NeoStem Announces Proposed Public Offering of Common Stock
7. NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
8. NeoStem Announces Agreement with Nankai Hospital in Tianjin to Offer NeoStems Licensed Orthopedic Technology
9. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
10. NeoStems Subsidiary Progenitor Cell Therapy Receives FACT Accreditation for Its New Allendale, New Jersey Manufacturing Facility
11. NeoStem to Present at 10th Annual Needham Healthcare Conference on Tuesday, April 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:7/31/2015)... ... July 31, 2015 , ... Creating one of the most ... pursuit of a visionary image that goes beyond the boundaries of fertility medicine. ... has reached extraordinary heights with dependable patient support, affordable treatments, unending hope, and high ...
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic ... across Georgia through the Girl Scout "Be a Friend First" program. Representatives from Peach ... 30. , “Peach State Health Plan and our parent company, Centene Corporation, are ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Mount Sinai ... research projects that evaluate the potential of related, experimental treatments. The collaboration moves into ... Health to award Columbia Care one of five state licenses to produce and dispense ...
(Date:7/31/2015)... ... , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in ... announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a ... MaxLife will grant 100% of the money raised to BioViva to help bring pioneering ...
Breaking Medicine News(10 mins):Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 2Health News:New Hope IVF Now Offers Most Affordable Assisted Reproductive Treatment in the UAE 3Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... A new study has revealed that one in ten people ... obesity. Earlier research that located the gene variant and // ... it was still ambiguous, whether people without the gene variant ... the link and understand it better, the researchers targeted the ...
... A research symposium titled ‘Challenging Intellectual Property’ will be ... York.// ,The Symposium will look into the ... of knowledge production in economic development. It will also ... on the table, desirous of bringing a change in ...
... famous saying that women buy for fun while men buy ... women may have more foot-healthy and comfortable// options this spring. ... heels, flat shoes and wedge heels. ,Dr. ... at Baylor University Medical Center at Dallas and president of ...
... medical services in Andhra Pradesh came to a ... strike enters the second day. ,Patients had ... services. Patients seeking immediate medical assistance had to ... at the Osmania General Hospital and the Gandhi ...
... Surgeons have now found a new surgical approach termed ... involuntary loss of urine//. It is a post operative ... a condition in which the vagina and the neighboring ... ,Most women who undergo the pelvic surgery are ...
... mistakes but what matters to the brain is the severity ... that is committed// by a person affects the brain. University ... human brain the instant a costly mistake occurs. Dr. Stephan ... the research said that the experiment was carried on to ...
Cached Medicine News:Health News:Doctors Strike In Andhra Enters The Second Day 2Health News:Two-In One Approach To Prevent Incontinence After Prolapse Surgery 2
... Reusable Purstring Device for use ... Biofragmentable Anastomosis Ring)., ,The ... intestinal, colorectal and esophageal surgery ... string sutures and is intended ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... Scantibodies Calcitonin Immunoassay is a two-site immunoradiometric ... Two different goat polyclonal antibodies to human ... to be specific for well-defined regions on ... determination of Calcitonin in human serum. ...
Fully automated Chemiluminescence assay for the measurement of calcitonin hormone in serum....
Medicine Products: